Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Chris is a Senior News Writer for Collider. He can be found in an IMAX screen, with his eyes watering and his ears bleeding for his own pleasure. He joined the news team in 2022 and accidentally fell ...

Dr. Bruce Levy's finding that Alex Maze died of shaken baby syndrome was critical in the murder conviction of his father, Russell Maze. Decades later, Levy says he believes Maze is innocent. In the ...

Erielle Sudario is a Collider News and Feature Author from Australia and has worked in the journalism industry since 2018. She has a passion for entertainment and pop culture news and has interviewed ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. Despite an extraordinary effort by the district attorney’s ...

Monday - Friday, 2:00 - 3:00 PM ET In this article Maze Therapeutics has had a great run since its initial public offering in January — and CEO Jason Coloma is hoping that momentum continues as the ...